A cohort study investigating aspirin use and survival in men with prostate cancer
Aspirin use has been associated with reduced mortality from cancer including prostate cancer in some studies. A number of anti-cancer mechanisms of aspirin have been proposed, including the inhibition of the cyclooxygenase enzymes, through which aspirin mediates both anti-platelet and anti-inflammat...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2014-01, Vol.25 (1), p.154-159 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 159 |
|---|---|
| container_issue | 1 |
| container_start_page | 154 |
| container_title | Annals of oncology |
| container_volume | 25 |
| creator | Flahavan, E.M. Bennett, K. Sharp, L. Barron, T.I. |
| description | Aspirin use has been associated with reduced mortality from cancer including prostate cancer in some studies. A number of anti-cancer mechanisms of aspirin have been proposed, including the inhibition of the cyclooxygenase enzymes, through which aspirin mediates both anti-platelet and anti-inflammatory activities. This cohort study examines associations between pre-diagnostic aspirin use (overall and by dose and dosing intensity) and mortality in men with localised prostate cancer.
Men with stage I–III prostate cancer were identified from Irish National Cancer Registry records, which have been linked to national prescribing data from the Irish General Medical Services scheme. Aspirin use in the year preceding prostate cancer diagnosis was identified from this linked prescription-claims data. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for associations between aspirin use and all-cause and prostate cancer-specific mortality. Associations between prescribed dose and dosing intensity were examined. The presence of effect modification by the type of treatment received and tumour characteristics was also assessed.
Two thousand nine hundred and thirty-six men with a diagnosis of stage I–III prostate cancer (2001–2006) were identified (aspirin users, n = 1131). The median duration of patient follow-up was 5.5 years. In adjusted analyses, aspirin use was associated with a small, but non-significant, reduced risk of prostate cancer-specific mortality (HR = 0.88, 95% CI 0.67–1.15). In dose–response analyses, stronger associations with prostate cancer-specific mortality were observed in men with higher aspirin dosing intensity (HR = 0.73, 95% CI 0.51–1.05) and in men receiving >75 mg of aspirin (HR = 0.61, 95% CI 0.37–0.99). Analyses of effect modification by treatment type or tumour characteristics were non-significant.
Consistent with prior studies, aspirin use was associated with a non-significant reduced risk of prostate cancer-specific mortality in men with localised prostate cancer. Men receiving higher doses of aspirin had a statistically significant reduced risk of prostate cancer-specific mortality. These findings regarding an aspirin dose require further investigation. |
| doi_str_mv | 10.1093/annonc/mdt428 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1490783179</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419359447</els_id><sourcerecordid>1490783179</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-73d967db3b3d29b337497ae2cd0713501770f94237e196f42d7bf6c64be1c8013</originalsourceid><addsrcrecordid>eNp10M9r2zAUwHFRVtr0x7HXoctgFy_6Fcs6lrCthcAodGchS8-Jii2nkpyR_74aTtfTTrp8eHrvi9AdJd8oUXxpQhiDXQ4uC9acoQVd1apqiKCf0IIoxiu54uISXaX0QgipFVMX6JIJvqprJhfo6R7bcTfGjFOe3BH7cICU_dZkH7bYpL2PPuApATbB4TTFgz-YvjA8QMB_fN7hfRxTNhmwNcFCvEHnnekT3J7ea_T7x_fn9UO1-fXzcX2_qaygJFeSO1VL1_KWO6ZazqVQ0gCzjkjKV4RKSTolGJdAVd0J5mTb1bYWLVDbEMqv0dd5bvn_dSpL68EnC31vAoxT0lQoIhtOpSq0mqktq6YInd5HP5h41JTovxX1XFHPFYv_fBo9tQO4f_o9WwFfTsAka_oulst9-nANLfdwUpycHZQQBw9RJ-uhVHI-gs3ajf4_K7wBdcWQOA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490783179</pqid></control><display><type>article</type><title>A cohort study investigating aspirin use and survival in men with prostate cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Flahavan, E.M. ; Bennett, K. ; Sharp, L. ; Barron, T.I.</creator><creatorcontrib>Flahavan, E.M. ; Bennett, K. ; Sharp, L. ; Barron, T.I.</creatorcontrib><description>Aspirin use has been associated with reduced mortality from cancer including prostate cancer in some studies. A number of anti-cancer mechanisms of aspirin have been proposed, including the inhibition of the cyclooxygenase enzymes, through which aspirin mediates both anti-platelet and anti-inflammatory activities. This cohort study examines associations between pre-diagnostic aspirin use (overall and by dose and dosing intensity) and mortality in men with localised prostate cancer.
Men with stage I–III prostate cancer were identified from Irish National Cancer Registry records, which have been linked to national prescribing data from the Irish General Medical Services scheme. Aspirin use in the year preceding prostate cancer diagnosis was identified from this linked prescription-claims data. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for associations between aspirin use and all-cause and prostate cancer-specific mortality. Associations between prescribed dose and dosing intensity were examined. The presence of effect modification by the type of treatment received and tumour characteristics was also assessed.
Two thousand nine hundred and thirty-six men with a diagnosis of stage I–III prostate cancer (2001–2006) were identified (aspirin users, n = 1131). The median duration of patient follow-up was 5.5 years. In adjusted analyses, aspirin use was associated with a small, but non-significant, reduced risk of prostate cancer-specific mortality (HR = 0.88, 95% CI 0.67–1.15). In dose–response analyses, stronger associations with prostate cancer-specific mortality were observed in men with higher aspirin dosing intensity (HR = 0.73, 95% CI 0.51–1.05) and in men receiving >75 mg of aspirin (HR = 0.61, 95% CI 0.37–0.99). Analyses of effect modification by treatment type or tumour characteristics were non-significant.
Consistent with prior studies, aspirin use was associated with a non-significant reduced risk of prostate cancer-specific mortality in men with localised prostate cancer. Men receiving higher doses of aspirin had a statistically significant reduced risk of prostate cancer-specific mortality. These findings regarding an aspirin dose require further investigation.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdt428</identifier><identifier>PMID: 24356627</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Aged ; Antineoplastic agents ; aspirin ; Aspirin - pharmacology ; Aspirin - therapeutic use ; Biological and medical sciences ; Cohort Studies ; Combined Modality Therapy ; Cyclooxygenase Inhibitors - pharmacology ; Cyclooxygenase Inhibitors - therapeutic use ; Gynecology. Andrology. Obstetrics ; Humans ; Male ; Male genital diseases ; Medical sciences ; Middle Aged ; mortality ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Nephrology. Urinary tract diseases ; pharmacoepidemiology ; Pharmacology. Drug treatments ; Proportional Hazards Models ; prostate neoplasm ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - therapy ; Risk ; Treatment Outcome ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>Annals of oncology, 2014-01, Vol.25 (1), p.154-159</ispartof><rights>2013 European Society for Medical Oncology</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-73d967db3b3d29b337497ae2cd0713501770f94237e196f42d7bf6c64be1c8013</citedby><cites>FETCH-LOGICAL-c410t-73d967db3b3d29b337497ae2cd0713501770f94237e196f42d7bf6c64be1c8013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28133730$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24356627$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Flahavan, E.M.</creatorcontrib><creatorcontrib>Bennett, K.</creatorcontrib><creatorcontrib>Sharp, L.</creatorcontrib><creatorcontrib>Barron, T.I.</creatorcontrib><title>A cohort study investigating aspirin use and survival in men with prostate cancer</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Aspirin use has been associated with reduced mortality from cancer including prostate cancer in some studies. A number of anti-cancer mechanisms of aspirin have been proposed, including the inhibition of the cyclooxygenase enzymes, through which aspirin mediates both anti-platelet and anti-inflammatory activities. This cohort study examines associations between pre-diagnostic aspirin use (overall and by dose and dosing intensity) and mortality in men with localised prostate cancer.
Men with stage I–III prostate cancer were identified from Irish National Cancer Registry records, which have been linked to national prescribing data from the Irish General Medical Services scheme. Aspirin use in the year preceding prostate cancer diagnosis was identified from this linked prescription-claims data. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for associations between aspirin use and all-cause and prostate cancer-specific mortality. Associations between prescribed dose and dosing intensity were examined. The presence of effect modification by the type of treatment received and tumour characteristics was also assessed.
Two thousand nine hundred and thirty-six men with a diagnosis of stage I–III prostate cancer (2001–2006) were identified (aspirin users, n = 1131). The median duration of patient follow-up was 5.5 years. In adjusted analyses, aspirin use was associated with a small, but non-significant, reduced risk of prostate cancer-specific mortality (HR = 0.88, 95% CI 0.67–1.15). In dose–response analyses, stronger associations with prostate cancer-specific mortality were observed in men with higher aspirin dosing intensity (HR = 0.73, 95% CI 0.51–1.05) and in men receiving >75 mg of aspirin (HR = 0.61, 95% CI 0.37–0.99). Analyses of effect modification by treatment type or tumour characteristics were non-significant.
Consistent with prior studies, aspirin use was associated with a non-significant reduced risk of prostate cancer-specific mortality in men with localised prostate cancer. Men receiving higher doses of aspirin had a statistically significant reduced risk of prostate cancer-specific mortality. These findings regarding an aspirin dose require further investigation.</description><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>aspirin</subject><subject>Aspirin - pharmacology</subject><subject>Aspirin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>Combined Modality Therapy</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>Cyclooxygenase Inhibitors - therapeutic use</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>mortality</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Nephrology. Urinary tract diseases</subject><subject>pharmacoepidemiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Proportional Hazards Models</subject><subject>prostate neoplasm</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Risk</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10M9r2zAUwHFRVtr0x7HXoctgFy_6Fcs6lrCthcAodGchS8-Jii2nkpyR_74aTtfTTrp8eHrvi9AdJd8oUXxpQhiDXQ4uC9acoQVd1apqiKCf0IIoxiu54uISXaX0QgipFVMX6JIJvqprJhfo6R7bcTfGjFOe3BH7cICU_dZkH7bYpL2PPuApATbB4TTFgz-YvjA8QMB_fN7hfRxTNhmwNcFCvEHnnekT3J7ea_T7x_fn9UO1-fXzcX2_qaygJFeSO1VL1_KWO6ZazqVQ0gCzjkjKV4RKSTolGJdAVd0J5mTb1bYWLVDbEMqv0dd5bvn_dSpL68EnC31vAoxT0lQoIhtOpSq0mqktq6YInd5HP5h41JTovxX1XFHPFYv_fBo9tQO4f_o9WwFfTsAka_oulst9-nANLfdwUpycHZQQBw9RJ-uhVHI-gs3ajf4_K7wBdcWQOA</recordid><startdate>201401</startdate><enddate>201401</enddate><creator>Flahavan, E.M.</creator><creator>Bennett, K.</creator><creator>Sharp, L.</creator><creator>Barron, T.I.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201401</creationdate><title>A cohort study investigating aspirin use and survival in men with prostate cancer</title><author>Flahavan, E.M. ; Bennett, K. ; Sharp, L. ; Barron, T.I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-73d967db3b3d29b337497ae2cd0713501770f94237e196f42d7bf6c64be1c8013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>aspirin</topic><topic>Aspirin - pharmacology</topic><topic>Aspirin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>Combined Modality Therapy</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>Cyclooxygenase Inhibitors - therapeutic use</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>mortality</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Nephrology. Urinary tract diseases</topic><topic>pharmacoepidemiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Proportional Hazards Models</topic><topic>prostate neoplasm</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Risk</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Flahavan, E.M.</creatorcontrib><creatorcontrib>Bennett, K.</creatorcontrib><creatorcontrib>Sharp, L.</creatorcontrib><creatorcontrib>Barron, T.I.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Flahavan, E.M.</au><au>Bennett, K.</au><au>Sharp, L.</au><au>Barron, T.I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A cohort study investigating aspirin use and survival in men with prostate cancer</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2014-01</date><risdate>2014</risdate><volume>25</volume><issue>1</issue><spage>154</spage><epage>159</epage><pages>154-159</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Aspirin use has been associated with reduced mortality from cancer including prostate cancer in some studies. A number of anti-cancer mechanisms of aspirin have been proposed, including the inhibition of the cyclooxygenase enzymes, through which aspirin mediates both anti-platelet and anti-inflammatory activities. This cohort study examines associations between pre-diagnostic aspirin use (overall and by dose and dosing intensity) and mortality in men with localised prostate cancer.
Men with stage I–III prostate cancer were identified from Irish National Cancer Registry records, which have been linked to national prescribing data from the Irish General Medical Services scheme. Aspirin use in the year preceding prostate cancer diagnosis was identified from this linked prescription-claims data. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for associations between aspirin use and all-cause and prostate cancer-specific mortality. Associations between prescribed dose and dosing intensity were examined. The presence of effect modification by the type of treatment received and tumour characteristics was also assessed.
Two thousand nine hundred and thirty-six men with a diagnosis of stage I–III prostate cancer (2001–2006) were identified (aspirin users, n = 1131). The median duration of patient follow-up was 5.5 years. In adjusted analyses, aspirin use was associated with a small, but non-significant, reduced risk of prostate cancer-specific mortality (HR = 0.88, 95% CI 0.67–1.15). In dose–response analyses, stronger associations with prostate cancer-specific mortality were observed in men with higher aspirin dosing intensity (HR = 0.73, 95% CI 0.51–1.05) and in men receiving >75 mg of aspirin (HR = 0.61, 95% CI 0.37–0.99). Analyses of effect modification by treatment type or tumour characteristics were non-significant.
Consistent with prior studies, aspirin use was associated with a non-significant reduced risk of prostate cancer-specific mortality in men with localised prostate cancer. Men receiving higher doses of aspirin had a statistically significant reduced risk of prostate cancer-specific mortality. These findings regarding an aspirin dose require further investigation.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>24356627</pmid><doi>10.1093/annonc/mdt428</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2014-01, Vol.25 (1), p.154-159 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1490783179 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Aged Antineoplastic agents aspirin Aspirin - pharmacology Aspirin - therapeutic use Biological and medical sciences Cohort Studies Combined Modality Therapy Cyclooxygenase Inhibitors - pharmacology Cyclooxygenase Inhibitors - therapeutic use Gynecology. Andrology. Obstetrics Humans Male Male genital diseases Medical sciences Middle Aged mortality Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Nephrology. Urinary tract diseases pharmacoepidemiology Pharmacology. Drug treatments Proportional Hazards Models prostate neoplasm Prostatic Neoplasms - mortality Prostatic Neoplasms - therapy Risk Treatment Outcome Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | A cohort study investigating aspirin use and survival in men with prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T22%3A42%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20cohort%20study%20investigating%20aspirin%20use%20and%20survival%20in%20men%20with%20prostate%20cancer&rft.jtitle=Annals%20of%20oncology&rft.au=Flahavan,%20E.M.&rft.date=2014-01&rft.volume=25&rft.issue=1&rft.spage=154&rft.epage=159&rft.pages=154-159&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdt428&rft_dat=%3Cproquest_cross%3E1490783179%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490783179&rft_id=info:pmid/24356627&rft_els_id=S0923753419359447&rfr_iscdi=true |